Stimcell Energetics Inc. (OTC: STME)

Stimcell Energetics Inc. is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products designed to enhance cellular function, promote general wellness, and alleviate health complications such as aging, insulin sensitivity, high blood pressure, neuropathy, and kidney function. The company operates in the biotechnology industry, specifically within the medical device sector, with a primary focus on its proprietary eBalance® Technology and its eBalance® Home System.

Stimcell Energetics generates revenue through the development, manufacturing, and potential sales of its eBalance® Pro and eBalance® Home Systems. These systems utilize microcurrent electrical therapy (MEY) to deliver subsensory micro amperage current to support general wellness or provide temporary relief of pain. The company's customer base includes healthcare professionals for the eBalance® Pro System and patients for the eBalance® Home System, targeting individuals managing complications caused by various pathological diseases and ailments.

• eBalance® Technology: This proprietary microcurrent technology is designed for the treatment of diabetes and related ailments. It utilizes bioelectric signals to modify and affect the behavior of cells, tissues, and organs. The technology is the cornerstone of the company's medical device systems, including the eBalance® Pro System for clinical settings and the eBalance® Home System for patient use at home. The eBalance® Technology aims to manage complications caused by various pathological diseases and ailments, such as pain, diabetes, insulin resistance, neuropathy, poor kidney function, high blood pressure, and metabolic syndrome.

• eBalance® Wellness: In February 2025, Stimcell Energetics partnered with ADM Tronics Unlimited, Inc. to redesign the eBalance® Home device into a compact, affordable consumer unit optimized for home use. This new device, expected to be completed in the fall of 2025 and ready for market in early 2026, will feature innovative diagnostics, including real-time assessment of cellular energy capacity, treatment tracking, and personalized user profiles. The wellness designation of the new device will negate the process of seeking approval for a medical device from the FDA, speeding up the time required to reach the market and lowering costs.

Stimcell Energetics operates in a highly competitive market for treatments that assist in the control and management of diabetes, its complications, and other ailments, including pain management. The company faces indirect competition from pharmaceutical companies producing various drugs to maintain and prevent diabetes-related complications, as well as companies producing glucose monitoring devices and other pharmaceuticals. Direct competitors in the electrical/microcurrent therapies include BodiHealth Systems, focusing on the pain relief market in the US, and Electromedical Products International, Inc., which developed Alpha-Stim® PPM for pain treatment using microcurrent therapy. The company's competitive advantage lies in its proprietary eBalance® Technology, which is not yet widely accepted in traditional medicine, allowing it to carve out a niche in the market.

The company's general customer base includes healthcare professionals and patients managing complications caused by various pathological diseases and ailments. Specific customers are not mentioned in the filing, but the target market includes individuals dealing with diabetes, insulin resistance, neuropathy, poor kidney function, high blood pressure, and metabolic syndrome. The eBalance® Home System is designed for direct use by patients to manage their symptoms at home, while the eBalance® Pro System is intended for use by healthcare professionals in clinical settings.